RxDoctor Payments Data

Luis Torrellas-Ruiz, MD

Pulmonary Disease · Humacao, PRNPI 1487765087

Payments from drug & device makers

$2,016in general payments, 2019–2025

Across 38 payments — averaging $53.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • GSK$298
  • AstraZeneca$131
  • PBG Puerto Rico LLC$38
  • Pfizer Pharmaceuticals LLC$18
  • Sanofi$18

What the payments were for

  • Consulting fees$1,21560%
  • Food & beverage$80140%

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim13$1,513
GSK14$298
AstraZeneca7$131
PBG Puerto Rico LLC2$38
Pfizer Pharmaceuticals LLC1$18
Sanofi1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,016 in reported general payments places this provider in the 40th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$11,443
Medicare patients
36
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Arnuity ElliptaFluticasone Furoate1,527$344,741
OfevNintedanib Esylate19$287,697
Stiolto RespimatTiotropium Br/Olodaterol Hcl325$160,367
Fasenra PenBenralizumab25$143,019
Trelegy ElliptaFluticasone/Umeclidin/Vilanter181$125,100
Wixela InhubFluticasone Propion/Salmeterol647$121,302
Breo ElliptaFluticasone/Vilanterol238$98,746
Albuterol Sulfate HfaAlbuterol Sulfate1,673$80,124
Dupixent PenDupilumab19$72,989
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate184$49,911
Pirfenidone33$48,134
NucalaMepolizumab12$43,822
Fluticasone Propionate2,776$40,508
Spiriva RespimatTiotropium Bromide73$39,210
SymbicortBudesonide/Formoterol Fumarate157$37,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta, Trelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta$298$664,0392,096 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$1,513$487,274417 claims
AstraZenecaSymbicort$131$37,572157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Humacao

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →